CN100522955C - 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 - Google Patents

含有新型强效紫杉烷的细胞毒性剂及其治疗用途 Download PDF

Info

Publication number
CN100522955C
CN100522955C CNB038232480A CN03823248A CN100522955C CN 100522955 C CN100522955 C CN 100522955C CN B038232480 A CNB038232480 A CN B038232480A CN 03823248 A CN03823248 A CN 03823248A CN 100522955 C CN100522955 C CN 100522955C
Authority
CN
China
Prior art keywords
group
carbon atoms
xsz
branched
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038232480A
Other languages
English (en)
Chinese (zh)
Other versions
CN1684948A (zh
Inventor
E·巴尔奥卢
M·米勒
R·V·J·沙里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/369,563 external-priority patent/US7390898B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CN1684948A publication Critical patent/CN1684948A/zh
Application granted granted Critical
Publication of CN100522955C publication Critical patent/CN100522955C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNB038232480A 2002-08-02 2003-07-14 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 Expired - Fee Related CN100522955C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21011202A 2002-08-02 2002-08-02
US10/210,112 2002-08-02
US10/369,563 2003-02-21
US10/369,563 US7390898B2 (en) 2002-08-02 2003-02-21 Cytotoxic agents containing novel potent taxanes and their therapeutic use

Publications (2)

Publication Number Publication Date
CN1684948A CN1684948A (zh) 2005-10-19
CN100522955C true CN100522955C (zh) 2009-08-05

Family

ID=31498026

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038232480A Expired - Fee Related CN100522955C (zh) 2002-08-02 2003-07-14 含有新型强效紫杉烷的细胞毒性剂及其治疗用途

Country Status (12)

Country Link
US (2) US7495114B2 (https=)
EP (1) EP1534674A4 (https=)
JP (1) JP2005539009A (https=)
KR (1) KR20050032110A (https=)
CN (1) CN100522955C (https=)
AU (1) AU2003247587B2 (https=)
BR (1) BR0313197A (https=)
CA (1) CA2494074A1 (https=)
IL (1) IL166624A0 (https=)
MX (1) MXPA05001390A (https=)
NO (1) NO20051108L (https=)
WO (1) WO2004013093A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
BRPI0511754A (pt) * 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
AU2006247471A1 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) * 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
EP2217063B1 (en) * 2007-11-08 2014-12-17 Virginia Tech Intellectual Properties, Inc. Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
ES2702400T3 (es) * 2010-02-03 2019-02-28 Oncbiomune Inc Composiciones que contienen un taxano o un taxoide y una proteína
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
JP6049642B2 (ja) 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
CN103648532A (zh) 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN105121419B (zh) * 2013-12-24 2016-08-03 于跃 Cabazitaxel类抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
ES2815353T3 (es) 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
WO2016090157A1 (en) 2014-12-04 2016-06-09 Celgene Corporation Biomolecule conjugates
EP3769787A1 (en) 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
SG10202106529XA (en) 2015-07-21 2021-07-29 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
KR20250171447A (ko) 2017-02-28 2025-12-08 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TW202413360A (zh) 2017-12-28 2024-04-01 美商伊繆諾金公司 苯二氮平衍生物
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
JP7561141B2 (ja) 2019-04-26 2024-10-03 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
MX2022010457A (es) 2020-02-25 2022-11-16 Mediboston Ltd Derivados de camptotecina y conjugados de esta.
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
JP2025524986A (ja) 2022-07-27 2025-08-01 メディボストン リミテッド オーリスタチン誘導体およびそのコンジュゲート

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5399726A (en) 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
US5728725A (en) 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US6028205A (en) 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US6339164B1 (en) 1993-01-29 2002-01-15 Florida State University C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
WO1996011683A1 (en) * 1994-10-14 1996-04-25 Hauser Chemical Research, Inc. New cytotoxic agents
WO1996023779A1 (en) * 1995-02-02 1996-08-08 Daiichi Pharmaceutical Co., Ltd. Ether derivative
CN1211919A (zh) * 1995-09-13 1999-03-24 佛罗里达州立大学 放射增敏性紫杉烷及其药物制剂
WO1997044026A1 (en) 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6545125B1 (en) 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
ES2276708T3 (es) * 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6175023B1 (en) 2000-01-31 2001-01-16 Jian Liu Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III
IL145637A0 (en) * 2000-02-02 2002-06-30 Univ Florida State Res Found C7 carbonate substituted taxanes as antitumor agents
AU778991B2 (en) * 2000-02-02 2004-12-23 Florida State University Research Foundation, Inc. C7 carbamoyloxy substituted taxanes as antitumor agents
AU776765B2 (en) * 2000-02-02 2004-09-23 Florida State University Research Foundation, Inc. C7 heterosubstituted acetate taxanes as antitumor agents
KR20010111580A (ko) * 2000-02-02 2001-12-19 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 개선된 용해도를 갖는 탁산 제형물
CZ20013523A3 (cs) * 2000-02-02 2002-03-13 Florida State University Research Foundation, Inc. Taxany s C10 heterosubstituovaným acetátem jako protinádorové látky
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Also Published As

Publication number Publication date
US20050085513A1 (en) 2005-04-21
IL166624A0 (en) 2006-01-15
US20050026997A1 (en) 2005-02-03
CA2494074A1 (en) 2004-02-12
EP1534674A2 (en) 2005-06-01
EP1534674A4 (en) 2007-11-28
JP2005539009A (ja) 2005-12-22
AU2003247587A1 (en) 2004-02-23
US7414073B2 (en) 2008-08-19
CN1684948A (zh) 2005-10-19
MXPA05001390A (es) 2005-07-29
WO2004013093A3 (en) 2004-07-01
WO2004013093A2 (en) 2004-02-12
US7495114B2 (en) 2009-02-24
KR20050032110A (ko) 2005-04-06
NO20051108L (no) 2005-05-02
BR0313197A (pt) 2005-08-09
AU2003247587B2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
CN100522955C (zh) 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
CA2485424C (en) Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
AU765588B2 (en) Cytotoxic agents comprising taxanes and their therapeutic use
US7390898B2 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078577

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1078577

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20110714